Company news

Fulcrum Therapeutics, Inc. news in 2023

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

November 8, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023

November 6, 2023

Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8: 00 a.m. ET

October 30, 2023

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

September 21, 2023

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

September 6, 2023

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

August 21, 2023

Fulcrum Therapeutics Appoints Chief Financial Officer

August 2, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

August 2, 2023

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8: 00 a.m. ET

July 26, 2023

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

July 9, 2023

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

May 14, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023

May 14, 2023

Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8: 00 a.m. ET

May 7, 2023

Fulcrum Therapeutics Announces CFO Resignation

April 4, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

March 8, 2023

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8: 00 a.m. ET

March 5, 2023

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

February 23, 2023

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

February 7, 2023

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

January 16, 2023

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

January 16, 2023

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

January 3, 2023

Fulcrum Therapeutics Announces CEO Transition

January 3, 2023

Calls in 2023

Decks in 2023